whatshot

SPRO   $1.35  0.75% Market Closed After Close 1.3692 1.42%

Spero Therapeutics Inc
show_chart Advanced Chart of SPRO
Last Events:

2023-08-09 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-06 Trend Power changed from almost flat to slow.

2023-08-05 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: exit from the overbought zone.

2023-08-04 Trend pattern changed from нисходящий клин to расходящийся клин с наклоном вниз.

2023-08-04 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-03 Trend pattern changed from сужающийся канал to нисходящий клин.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 2
Target Price Mean 7.50
Mean unverified/preliminary 7.50 / 7.50
Target Price Low / High 7.00 / 8.00
Median / STD DEV 7.50 / 0.71
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi Sell ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 Sell ActivelyBuy None
ma50 None None None
ma100 Buy Buy ActivelyBuy
Candlestick PatternSept. 6, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US84833T1034
ceo Mr. Satyavrat Shukla C.F.A.
Website https://sperotherapeutics.com
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.